)
Cipla (CIPLA) investor relations material
Cipla Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 FY26 revenue was INR 7,074 crore, flat year-over-year, with India business up 10% YoY and strong chronic therapy growth, while U.S. revenues were impacted by lower Lenalidomide and lanreotide sales.
Strategic launches included Afrezza and Mounjaro in India, exclusive marketing/distribution deals with Pfizer, and acquisitions of Inzpera Healthsciences and Esperer Onco Nutrition.
North America saw Albuterol maintain #1 market share, but lanreotide supply was disrupted due to FDA observations; resupply expected in H1 FY27.
Unaudited financial results for Q3 FY26 were approved, with financial statements reviewed and receiving an unmodified review conclusion.
Exceptional item of INR 276 crore recognized due to increased employee benefit liabilities from new labour codes.
Financial highlights
EBITDA margin was 17.7% for Q3 FY26, down due to lower generic revenues and product mix; EBITDA at INR 1,255 crore.
Gross margin after material costs was 62.8%, affected by Lenalidomide decline and R&D/API purchases.
PAT was INR 676 crore (9.6% of sales), down 57% YoY, impacted by a one-time labour code expense.
R&D spend was INR 419–494 crore (7% of revenue), up 37.4% YoY, focused on filings and pipeline development.
Net cash position at INR 10,229 crore; total debt at INR 489 crore as of Dec 31, 2025.
Outlook and guidance
FY26 EBITDA margin guidance revised to around 21% due to lower-than-expected lanreotide and Lenalidomide performance.
U.S. revenue guidance for FY27 will be revised downward due to lanreotide disruption, but new launches are expected to support growth.
R&D spend expected to normalize to 5-6% of revenue, with some lumpiness based on project timing.
Acquisition of perpetual rights to manufacture and market Galvus brands for INR 1,107 crore, effective Jan 2026, to strengthen diabetes portfolio.
Next Cipla earnings date
Next Cipla earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)